Hypothesis

Rapamycin extends lifespan not by reversing global chromatin decay but by selectively preserving the three‑dimensional architecture of stress‑responsive super‑enhancers through enhanced Mediator phase separation. This creates a transient, pseudo‑youthful transcriptional program that mimics the adaptive state induced by caloric restriction while the bulk of the epigenome continues to age.

Mechanistic Reasoning

1. mTORC1 inhibition alters nuclear condensates – Rapamycin reduces phosphorylation of MED1 and other IDR‑rich Mediator subunits, promoting their liquid‑liquid phase separation and increasing local concentration at super‑enhancers that drive autophagy, lysosomal, and oxidative‑stress genes (see Rapamycin mimics CR).
2. Selective loop stabilization – In aged hematopoietic stem cells (HSCs) and muscle satellite cells, global TAD insulation and super‑enhancer rewiring proceed (loss of intra‑TAD contacts, gain of inflammatory H3K27ac) (Chromatin aging in muscle stem cells; HSC chromatin erosion). Rapamycin‑induced Mediator condensates preferentially reinforce existing promoter‑enhancer contacts at stress‑resistance loci, thereby rescuing their transcriptional output without restoring the youthful chromatin landscape elsewhere.
3. Trade‑off outcome – Cells retain a "harder‑life" transcriptional signature (high autophagy, low protein synthesis) that confers stress resistance and extends lifespan, yet the underlying epigenetic erosion—broadened H3K4me3 domains, increased bivalency, loss of H4K16ac polarity—persists, limiting true rejuvenation.

Testable Predictions

• Prediction 1: Hi‑C or Capture‑C analysis of rapamycin‑treated aged HSCs will show a significant increase in specific loops linking stress‑responsive super‑enhancers (e.g., at Foxo3, Sirt1, Lamp2) to their promoters, while global TAD insulation scores and average intra‑TAD contacts remain unchanged compared with untreated aged controls.
• Prediction 2: Pharmacological or genetic disruption of Mediator phase separation (e.g., MED1 IDR mutation, 1,6‑hexanediol treatment, or CRISPR‑mediated knock‑down of MED1) will abolish rapamycin‑mediated loop stabilization at these loci and concomitantly shorten lifespan in treated mice, without affecting rapamycin’s inhibition of mTORC1 signaling (as verified by p‑S6K levels).
• Prediction 3: Transcriptomic profiling will reveal that rapamycin sustains youthful expression of stress‑resistance genes but fails to re‑activate lineage‑specific super‑enhancers driving myogenic or hematopoietic differentiation programs, mirroring the persistent chromatin defects observed in aging.

Falsification

If rapamycin treatment does not produce selective enhancer‑promoter loop enrichment at stress‑responsive loci, or if disrupting Mediator phase separation leaves loop patterns and lifespan extension unchanged, the hypothesis is falsified. Conversely, confirmation of selective loop preservation coupled with dependence on Mediator condensates would support the model.

References

• Rapamycin mimics caloric restriction: Rapamycin mimics CR
• Chromatin aging in muscle stem cells: Chromatin aging in muscle stem cells
• Hematopoietic stem cell chromatin erosion: HSC chromatin erosion